Answers are grounded in this paper and cite their sources.
The discovery that 1-deoxynojirimycin restores mitochondrial health and prevents cardiac hypertrophy in preclinical models suggests a novel therapeutic approach for hypertrophic cardiomyopathy.
Hypertrophic cardiomyopathy and pathological cardiac hypertrophy are characterized by mitochondrial structural and functional abnormalities. In this issue of the JCI, Zhuang et al. discovered 1-deoxynojirimycin (DNJ) through a screen of mitochondrially targeted compounds. The authors described the effects of DNJ in restoring mitochondria and preventing cardiac myocyte hypertrophy in cellular models carrying a mutant mitochondrial gene, MT-RNR2, which is causally implicated in familial hypertrophic cardiomyopathy. DNJ worked via stabilization of the mitochondrial inner-membrane GTPase OPA1 and other, hitherto unknown, mechanisms to preserve mitochondrial crista and respiratory chain components. The discovery is likely to spur development of a class of therapeutics that restore mitochondrial health to prevent cardiomyopathy and heart failure.
No takes yet. Share an insight, caveat, or question.
Abhinav Diwan (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: